Method and device for obtaining genome variation data set and storage medium

By using T2T genome assembly and Mendel's law of genetic co-isolation of family genetics, the problems of missed and misdetection of pathogenic variants in gene sequencing technology are solved, and the quality of variant detection and accuracy of new variant detection are improved. .

CN119091955APending Publication Date: 2024-12-06BEIJING GRANDOMICS BIOTECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411153473.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing gene sequencing technology relies on traditional reference genome alignment, resulting in the pathogenic variants that may be missed or misdetected in the genome gap region or error region, and the T2T-CHM13 genome is derived only from a nearly homozygous complete hydatidiform sample. The lack of global population representation has led to the detection of non-pathogenic variants increasing the difficulty of subsequent verification.

Method used

Using the genome assembly method, the T2T genome is used as the reference baseline, and the genome assembly is performed by sequencing sequences of the subjects to be tested and their parents, and a high-quality T2T genome is generated, and variant alignment and call are performed. Combined with Mendel's genetic law and family genetic co-isolation Evidence, confirm new or pathogenic variants.

Benefits of technology

It significantly improves the quality of genomic variant detection, narrows the scope of candidate variant targets, reduces the subsequent verification workload, and improves the quality of detection of new variants and the accuracy of pathogenicity confirmation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119091955A_ABST
    Figure CN119091955A_ABST
Patent Text Reader

Abstract

The invention discloses a method and device for obtaining a genome variation data set and a storage medium. The method comprises the following steps: obtaining sequencing sequences of a to-be-detected object and father and mother of the to-be-detected object; carrying out genome assembly on the sequencing sequence of the to-be-detected object or the father or mother of the to-be-detected object, and taking the assembled genome as a reference baseline; comparing the sequencing sequences of the to-be-detected object and the father and mother of the to-be-detected object with the reference baseline, and performing variation calling to obtain a variation data set of the to-be-detected object. According to the method and the device, the genome assembly sequence of the sequencing sequence of the to-be-detected object or the father or mother of the to-be-detected object is used as the reference baseline for variation detection, so that the detection quality of variation in a complex region of the genome is improved, a variation data set can be remarkably reduced, and the workload of subsequent variation verification is reduced. The variation data set obtained by the method or the device can be used for quickly detecting various known variations and unknown new variations, so that the detection quality of the new variations can be improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of genome variation detection and analysis, and in particular to a method, device and storage medium for obtaining a genome variation data set. Background Art

[0002] In recent years, with the development of gene sequencing technology, gene sequencing technology represented by the second-generation sequencing technology (NGS) has completely changed the field of genomics and is rapidly changing clinical diagnosis and precision medicine. A variety of gene sequencing technologies have become a powerful tool for identifying pathogenic variants, thereby helping medical staff to quickly diagnose patients and develop personalized treatment strategies. Different sequencing technologies have different coverage breadth and sequencing depth, which will affect the final variant detection. At present, among the common genetic testing technologies in clinical practice, the sequencing coverage breadth ranges from small to large, including targeted panel sequencing, whole exome sequencing (WES), and whole genome sequencing (WGS).

[0003] Targeted panel sequencing refers to targeted enrichment of only the regions of interest in the genome, followed by library construction and sequencing, and comparison of the sequencing results with the reference genome (such as GRCh37 / GRCh38) to obtain variant screening results for specific genes. The advantages of panel sequencing are simplicity, speed, low price, high sequencing depth, and easy detection of low-frequency mutations. The limitation is that it only focuses on specific target areas of known diseases, and potential pathogenic variants outside the target area will be missed.

[0004] WES is a targeted enrichment of all exon regions in the genome. After library construction and sequencing, it is compared with the reference genome (such as GRCh37 / GRCh38) to obtain genetic variation results within the entire exon range. WES is a relatively comprehensive and cost-effective detection method as a whole. However, the biggest limitation of WES is that it cannot detect genetic variations in non-coding regions. In addition, the coverage of WES in the exon region is also susceptible to capture efficiency and sequence GC content.

[0005] WGS sequences the entire genome of the subject. In theory, it includes not only the coding and non-coding regions of all genes, but also the intergenic regions. Compared with WES, WGS can effectively avoid technical deviations caused by targeted enrichment, such as GC preference; at the same time, its sequencing coverage is wider and variant screening is more comprehensive. However, due to the relatively expensive price of WGS, in clinical practice, medical staff often recommend Panel sequencing and WES sequencing based on the clinical manifestations of the subjects, and WGS is more of a supplement to the former two.

[0006] Trio-based WGS sequencing is developed on the basis of traditional WGS sequencing technology. Since the amount of variation data obtained by WGS sequencing is usually large, and many of them are VUS variations with unclear clinical significance, this poses a challenge to the orthogonal verification of genetic variations and the discovery of pathogenic variations. In view of this, in clinical practice, genome sequencing is usually performed on the proband Trio family in order to clarify the pathogenicity of the variation site through Mendel's law of inheritance and evidence of pedigree genetic co-segregation, thereby effectively improving the disease detection rate. For example, for some variants with unknown pathogenicity, if it is confirmed to be a new variation (PS2) in the biological parents through family testing, further evidence can be added to clarify the pathogenicity. For this reason, Trio-based WGS sequencing is considered to be the best practice of clinical genetic testing technology. It can not only avoid the GC preference generated by targeted sequencing technologies such as panels and WES, but also cover the entire genomic region. At the same time, it can also exclude some non-pathogenic variations inherited from parents and discover new variations through Mendel's law and evidence of pedigree genetic co-segregation. However, this technology requires that the sequencing sequences of parents and offspring be compared with the reference genome and variants detected, which makes the quality of its final variant detection severely restricted by the integrity, continuity and accuracy of the reference genome. If the pathogenic variant exists in the gap region or error region of the traditional reference genome, it may be missed or misdetected, which is unacceptable for clinical testing.

[0007] In summary, in terms of variant detection strategies, the above gene sequencing technologies are highly dependent on the comparison of sequencing sequences with traditional reference genomes. However, the human reference genomes GRCh37 and GRCh38 commonly used in clinical practice today are not perfect, and there are still many gaps and inaccurate local assembly problems. Directly comparing the sequences obtained by WGS sequencing with GRCh37 or GRCh38 may result in missed detection of pathogenic variants (variants located in the gap area of ​​the genome) or false detection (variants located in the inaccurate area of ​​the genome). Therefore, further improving the quality of the reference genome is particularly beneficial for variant detection.

[0008] In 2022, with the advantages of third-generation long-read sequencing, the T2T Alliance released the first human T2T genome CHM13 that is close to 0gap, marking the entry of genome sequencing into the T2T era. Compared with the latest version of the reference genome GRCh38, the T2T-CHM13 genome adds nearly 200Mb of sequence, fills about 8% of the blank areas of the genome, and corrects a large number of inaccurately assembled areas. Subsequently, the variation detection strategy based on the T2T-CHM13 genome has been shown to greatly improve the quality of genome variation detection.

[0009] In the process of implementing this strategy, for the short read sequences of the subjects, the BWA-MEM software was used to align the short read sequences to the T2T-CHM13 genome, and the GATK HaplotypeCaller was used to call the SNV and indel variants; for the long read sequences of the subjects, such as HiFi and ONT sequences, Winnowmap or minimap2 was used to align the long read sequences to the T2T-CHM13 genome, and Sniffles was used to call the SV variants. The variant calling results showed that compared with the traditional reference genome hg38, the variant calling strategy based on the T2T-CHM13 genome significantly increased the number of variants in previously unresolved regions and corrected the original large number of false variants (Sergey Aganezov et al., A complete reference genome improves analysis of human genetic variation. Science 376, eabl3533 (2022). DOI: 10.1126 / science.abl3533).

[0010] Although the variant detection strategy based on the T2T-CHM13 genome can significantly improve the quality of variant detection, the T2T-CHM13 genome is only derived from a nearly homozygous complete hydatidiform mole sample and is not representative of the global population. If it is simply used as a reference for variant comparison, due to the genomic polymorphism among populations, it will inevitably lead to the detection of a large number of non-pathogenic variants, thereby greatly increasing the workload of subsequent variant verification and the difficulty of screening pathogenic variants.

[0011] Therefore, it is necessary to develop a new genomic variation detection strategy that can not only take advantage of the advantages of using the T2T genome as a reference, but also significantly narrow the final range of candidate variation targets. Summary of the invention

[0012] In order to achieve the above objectives, this application adopts the following technical solutions:

[0013] The first aspect of the present application discloses a method for obtaining a genomic variation dataset, comprising the following steps:

[0014] The step of obtaining a sequencing sequence includes obtaining the sequencing sequence of the subject to be tested and his / her father and mother;

[0015] A genome assembly step, comprising assembling a genome of the sequencing sequence of the subject or his / her father or his / her mother, and using the assembled genome as a reference baseline;

[0016] The step of obtaining the variation data set includes comparing the sequencing sequences of the subject to be tested and its father and mother with the reference baseline and performing variation calling to obtain the variation data set of the subject to be tested.

[0017] Preferably, the genome assembly is a T2T genome assembly.

[0018] Preferably, the genome assembly is a haplotype-resolution assembly or a folded-type assembly of a T2T genome assembly.

[0019] Preferably, the assembled genome satisfies that at least one chromosome is assembled to a telomere-to-telomere gap-free level, and the assembly quality of the entire genome is greater than that of the reference genome GRCh38.

[0020] The second aspect of the present application discloses a method for detecting genomic variation, comprising: 1) obtaining a genomic variation data set using the above-mentioned method of the present application; 2) annotating the variation data set; 3) screening the annotated variation data set to obtain candidate genomic variation; 4) confirming novel variation in the candidate genomic variation based on Mendel's law of inheritance; or, confirming or excluding suspected pathogenic variation in the candidate genomic variation based on evidence of familial genetic co-segregation.

[0021] For the purposes of this application, a "de novo variant" refers to a variant found in the subject but not in his or her parents; a "pathogenic variant" refers to any genomic variant that may cause disease.

[0022] When the detection target is a new variant, the new variant can be further confirmed based on Mendel's law of inheritance after obtaining the candidate genomic variant. When the detection target is a pathogenic variant, the suspected pathogenic variant can be further confirmed or excluded based on the evidence of familial genetic co-segregation after obtaining the candidate genomic variant. For example, if the inheritance pattern of a variant is AD, if the parent's phenotype is normal and carries the same variant as the subject, the pathogenicity of the candidate variant can be preliminarily excluded; if the parent's phenotype is similar to the subject and both are ill, and carry the same variant as the subject, the pathogenicity of the candidate variant can be preliminarily confirmed.

[0023] Those skilled in the art will appreciate that all or part of the functions of the above method can be implemented by hardware or by computer program. When all or part of the functions in the above method are implemented by computer program, the program can be stored in a computer-readable storage medium, and the storage medium can include: read-only memory, random access memory, disk, CD, hard disk, etc., and the program is executed by a computer to implement the above functions. For example, the program is stored in the memory of the device, and when the program in the memory is executed by the processor, all or part of the above functions can be implemented. In addition, when all or part of the functions in the above implementation are implemented by computer program, the program can also be stored in a storage medium such as a server, another computer, disk, CD, flash disk or mobile hard disk, and saved in the memory of the local device by downloading or copying, or the system of the local device is updated, and when the program in the memory is executed by the processor, all or part of the functions in the above method can be implemented.

[0024] The third aspect of the present application discloses a device for obtaining a genome variation data set, comprising a sequencing sequence acquisition module, a genome assembly module and a variation data set acquisition module, wherein:

[0025] The sequencing sequence acquisition module is used to obtain the sequencing sequences of the subject to be tested and his or her father and mother;

[0026] The genome assembly module is used to assemble the genome of the sequencing sequence of the subject to be tested or his father or his mother, and the assembled genome is used as a reference baseline;

[0027] The variant data set acquisition module is used to compare and call variants of the sequencing sequences of the subject to be tested and its father and mother with the reference baseline respectively, so as to obtain the variant data set of the subject to be tested.

[0028] It should be noted that the device for obtaining a genomic variation data set in the present application actually implements the method for obtaining a genomic variation data set in the present application through each module respectively; therefore, the specific limitations of each module can refer to the corresponding steps in the method for obtaining a genomic variation data set in the present application, and will not be repeated here.

[0029] It should also be noted that the sequencing sequence acquisition module of the present application is mainly used to obtain the sequencing sequences of the subject to be tested and its father and mother. As for the specific method of obtaining the sequencing sequence, it can refer to the prior art depending on the situation. For example, the sequencing sequence stored in the sequencing device can be directly connected and called, or the sequencing sequence stored in another storage device or web page can be accessed and called through the network, or the sequencing sequence stored in an external storage device, such as a USB flash drive, a mobile hard disk, etc. can be accessed and called; or a storage module can be added to the device of the present application according to the needs, and the sequencing sequence is stored in the storage module. The sequencing sequence acquisition module directly accesses the storage module to obtain the sequencing sequence. When calling these sequencing sequences, according to the product design, the sequencing sequence acquisition module can also temporarily store or long-term store the sequencing sequence it calls.

[0030] It can be understood that the names of the sequencing sequence acquisition module, genome assembly module and variation data set acquisition module of the present application correspond to the names of the steps in the method for obtaining a genome variation data set of the present application, so as to facilitate intuitive understanding of the functions and effects of each module; in fact, the names of these modules can also be simply set to module one, module two, module three, as long as the functions of the present application can be achieved.

[0031] The fourth aspect of the present application discloses a device for detecting genome variation, comprising:

[0032] A sequencing sequence acquisition module is used to obtain the sequencing sequences of the subject to be tested and his or her father and mother;

[0033] A genome assembly module, used to assemble the genome of the sequencing sequence of the subject to be tested or his father or his mother, and use the assembled genome as a reference baseline;

[0034] A variant data set acquisition module is used to compare and call variants of the sequencing sequences of the subject to be tested and its father and mother with the reference baseline respectively, to obtain a variant data set of the subject to be tested;

[0035] An annotation module, used for annotating the variant data set obtained by the variant data set obtaining module;

[0036] A screening module, used to screen the annotated variant data set to obtain candidate genomic variants;

[0037] The confirmation module is used to confirm the novel variation among the candidate genomic variation based on Mendel's law of inheritance; or to confirm or exclude the suspected pathogenic variation among the candidate genomic variation based on the evidence of familial genetic co-segregation.

[0038] The fifth aspect of the present application discloses a device for obtaining a genomic variation dataset, the device comprising a memory and a processor, wherein the memory is used to store a program; the processor is used to implement the method for obtaining a genomic variation dataset of the present application by executing the program.

[0039] The sixth aspect of the present application discloses a computer-readable storage medium, in which a program is stored. The program can be executed by a processor to implement the method of obtaining a genomic variation dataset of the present application.

[0040] The seventh aspect of the present application discloses a device for detecting genome variations, which includes a memory and a processor, wherein the memory is used to store programs; and the processor is used to implement the method for detecting genome variations of the present application by executing the programs.

[0041] The eighth aspect of the present application discloses a computer-readable storage medium, in which a program is stored. The program can be executed by a processor to implement the method of genome variation detection of the present application.

[0042] The beneficial effects of this application are:

[0043] The method and device for obtaining a genomic variation data set in the present application uses the genome assembly sequence of the sequencing sequence of the subject to be tested or its father or mother as a reference baseline for variation detection, which is beneficial to improving the detection quality of variations in complex regions of the genome and significantly reducing the variation data set, thereby reducing the workload of subsequent variation verification. The variation data set obtained in the present application can be used in human disease variation detection scenarios. Combined with Mendel's laws of inheritance, it can also be used for the rapid detection of new variations in offspring, which helps to improve the detection quality of new variations; combined with pedigree genetic co-segregation evidence, it can be used to confirm or exclude suspicious candidate pathogenic variations. After the coordinates are converted into a variation data set based on hg19 / hg38, the existing annotation information, database resources, etc. can also be directly used for pathogenicity prediction. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 It is the number of small variants obtained by comparing the LCL5 Illumina sequence in the embodiment of the present application based on hg19, hg38, T2T-CHM13, and LCL7 respectively;

[0045] Figure 2 It is the number of small mutations obtained by comparing the LCL5 HiFi sequence in the embodiment of the present application based on hg19, hg38, T2T-CHM13, and LCL7 respectively;

[0046] Figure 3is the number of SV variations obtained by comparing the LCL5 HiFi sequence in the embodiment of the present application based on hg19, hg38, T2T-CHM13, and LCL7 respectively;

[0047] Figure 4 is the number of small mutations obtained by comparing the LCL5 HiFI sequence in the embodiment of the present application based on hg38, T2T-CHM13, and LCL8;

[0048] Figure 5 It is the number of small variations obtained by comparing the LCL8 HiFI sequence in the examples of the present application based on hg38 and LCL5. DETAILED DESCRIPTION

[0049] Some technical terms involved in this application are explained as follows:

[0050] Next-generation sequencing: Next-generation sequencing (NGS) is a high-throughput sequencing technology that can sequence tens or millions of DNA molecules in parallel at one time. The read length of next-generation sequencing is relatively short, usually 150bp, 250bp or 300bp, and generally does not exceed 500bp.

[0051] Third-generation sequencing: The third-generation sequencing is a single molecule real-time sequencing technology, also known as long-read sequencing. Different from the traditional second-generation sequencing technology, the third-generation sequencing has a longer read length, which can help solve the problem of difficult assembly of repeated and complex regions in the genome assembly process.

[0052] Variant calling: refers to the sequencing and differential analysis of the genome of an individual or group of a species through sequencing technology to obtain a large amount of genetic variation information such as single nucleotide polymorphism (SNP), insertion and deletion (indel), structural variation (SV), etc.

[0053] Variants of unknown significance (VUS variants): refers to unknown or relatively rare variants found in genetic testing. They generally cannot be classified as variants with known risks or benefits. They are only genetic variants with unknown clinical significance.

[0054] Targeted Panel Sequencing: Targeted Panel Sequencing refers to targeted enrichment of only the regions of interest in the genome, followed by library construction and sequencing, and comparing the sequencing results with the reference genome to obtain variant screening results for specific genes.

[0055] Whole exome sequencing (WES): WES is a targeted enrichment of all exon regions in the genome. After library construction and sequencing, it is compared with the reference genome to obtain genetic variation results within the entire exome.

[0056] Whole genome sequencing (WGS): WGS is the sequencing of the entire genome of the subject. In theory, in addition to the coding and non-coding regions of all genes, it also includes intergenic regions.

[0057] Reads (sequencing sequence): The original fragments generated during sequencing. The reads generated by second-generation sequencing are shorter, with an average of tens to hundreds of bp. If the second-generation sequencing is performed on both ends, paired-end sequencing reads will be generated. The average read length of the reads generated by the third-generation sequencing technology can reach 10kbp.

[0058] Contigs: There are overlaps between different reads. Different reads are assembled according to the overlapping areas to form a larger fragment called a contig.

[0059] Genome assembly: The reads generated by sequencing are spliced ​​according to certain rules to finally generate the full base sequence of the genome. Genome assembly can be divided into two types: de novo genome assembly and reference genome assembly.

[0060] T2T genome: Through the combination of multiple sequencing technologies such as PacBio HiFi, OxfordNanopore (ONT), and Hi-C, a high-quality genome with seamless telomere-to-telomere sequence of one or more chromosomes is achieved.

[0061] Haploid genome: In genetics, it refers to the combination of a series of genetic variation sites on a single chromosome.

[0062] Collapsed genome: During the genome assembly process, two homologous chromosomes from each parent are folded together, finally forming a genome that is actually a mosaic.

[0063] Trio: refers to a family that undergoes genetic sequencing, which consists of a parent and a single child.

[0064] The present application is further described in detail below through specific examples. The following examples are only used to further illustrate the present application and should not be construed as limiting the present application.

[0065] Example

[0066] The specific steps for obtaining the subject's genomic variation dataset in this example are as follows:

[0067] 1. Obtain sequencing sequences of the subject and his / her father and mother. Specifically, the father of the subject will undergo second-generation short-read sequencing (Illumina or BGI), third-generation long-read sequencing (HiFi sequencing and ONT sequencing), and Hi-C sequencing; the subject and the mother of the subject will undergo second-generation short-read sequencing (Illumina or BGI) or third-generation long-read sequencing (HiFi sequencing or ONT sequencing).

[0068] 2. Use the sequencing sequence of the subject's father to perform T2T genome assembly on the subject's father to obtain the T2T genome of the subject's father. The optional T2T assembly strategies are as follows:

[0069] 2.1 The ONT sequence and HiFi sequence from the subject’s father were assembled separately.

[0070] 2.2 De-redundancy of the assembly results of the two lines based on the genome size of the subject’s father.

[0071] 2.3 Perform Hi-C mounting on the assembly results of the two lines respectively.

[0072] 2.4 Perform HiFi error correction on the centromere region of the ONT line genome and perform second-generation error correction on the entire genome region.

[0073] 2.5 Assemble and extend the telomere region.

[0074] 2.6 Perform Gap filling and HiFi error correction on the genomes assembled by the two routes respectively.

[0075] 2.7 Adjust the assembled version in combination with the known reference genome, and output the T2T assembly version of the subject's father with the best assembly quality.

[0076] 3. Compare and detect mutations in the second-generation sequencing sequences or third-generation sequencing sequences of the subject and his / her parents with the T2T genome of the subject's father obtained in step 2 to obtain a mutation data set.

[0077] In another implementation of this example, the specific steps of obtaining the subject's genomic variation dataset are as follows:

[0078] 1. Obtain sequencing sequences of the subject and his / her parents. Specifically, perform second-generation short-read sequencing (Illumina or BGI), third-generation long-read sequencing (HiFi sequencing and ONT sequencing), and Hi-C sequencing on the subject's mother; perform second-generation short-read sequencing (Illumina or BGI) or third-generation long-read sequencing (HiFi sequencing or ONT sequencing) on ​​the subject and the subject's father.

[0079] 2. Perform T2T genome assembly on the mother of the subject using the sequencing sequence of the mother of the subject to obtain the T2T genome of the mother of the subject. The optional T2T assembly strategies are as follows:

[0080] 2.1 The ONT sequence and HiFi sequence from the subject's mother were assembled separately.

[0081] 2.2 De-redundancy of the assembly results of the two lines based on the genome size of the subject's mother.

[0082] 2.3 Perform Hi-C mounting on the assembly results of the two lines respectively.

[0083] 2.4 Perform HiFi error correction on the centromere region of the ONT line genome and perform second-generation error correction on the entire genome region.

[0084] 2.5 Assemble and extend the telomere region.

[0085] 2.6 Perform Gap filling and HiFi error correction on the genomes assembled by the two routes respectively.

[0086] 2.7 Adjust the assembled version in combination with the known reference genome, and output the T2T assembly version of the subject's mother with the best assembly quality.

[0087] 3. Compare and detect mutations in the second-generation sequencing sequences or third-generation sequencing sequences of the subject and his / her parents with the T2T genome of the subject's mother obtained in step 2 to obtain a mutation data set.

[0088] In another implementation of this example, the specific steps of obtaining the subject's genomic variation dataset are as follows:

[0089] 1. Obtain sequencing sequences of the subject and his / her parents. Specifically, perform second-generation short-read sequencing (Illumina or BGI), third-generation long-read sequencing (HiFi sequencing and ONT sequencing), and Hi-C sequencing on the subject; perform second-generation short-read sequencing (Illumina or BGI) or third-generation long-read sequencing (HiFi sequencing or ONT sequencing) on ​​the subject's father and mother.

[0090] 2. Use the sequencing sequence of the subject to assemble the T2T genome of the subject to obtain the T2T genome of the subject. The optional T2T assembly strategies are as follows:

[0091] 2.1 Assemble the ONT sequence and HiFi sequence derived from the subject separately.

[0092] 2.2 De-redundancy of the assembly results of the two lines based on the genome size of the subject.

[0093] 2.3 Perform Hi-C mounting on the assembly results of the two lines respectively.

[0094] 2.4 Perform HiFi error correction on the centromere region of the ONT line genome and perform second-generation error correction on the entire genome region.

[0095] 2.5 Assemble and extend the telomere region.

[0096] 2.6 Perform Gap filling and HiFi error correction on the genomes assembled by the two routes respectively.

[0097] 2.7 Adjust the assembled version in combination with the known reference genome, and output the T2T assembly version of the subject with the best assembly quality.

[0098] 3. The second-generation sequencing sequences or third-generation sequencing sequences of the subject and his / her parents are compared and tested for mutations with the T2T genome of the subject obtained in step 2 to obtain a mutation data set.

[0099] According to the above method, in this example, the genome of the father of the subject is assembled as a reference baseline to obtain a variant data set, the genome of the mother of the subject is assembled as a reference baseline to obtain a variant data set, and the genome of the subject is assembled as a reference baseline to obtain a variant data set. The details are as follows:

[0100] Experiment 1 Assemble the T2T genome of the subject's father LCL7 as a reference baseline

[0101] 1. Obtain the genome data generated by the publicly available Chinese Pedigree No. 1 standard material. Chinese Pedigree No. 1 is a Quartet pedigree, including both parents and a pair of identical twin daughters. In this example, the Illumina sequence, HiFi sequence, ONT sequence, and Hi-C sequence of the twin father LCL7 are downloaded for the subsequent assembly of the father LCL7 T2T genome; the second-generation Illumina sequence and the third-generation HiFi sequence of the twin daughter LCL5 and her father LCL7 and mother LCL8 are downloaded for subsequent comparison and variation screening.

[0102] 2. Assemble the T2T genome of father LCL7. The specific steps include:

[0103] 2.1 The second-generation Illumina sequence of the father’s LCL7 was used to conduct a genome survey to estimate the genome size, heterozygosity, repetitive sequence ratio, GC content, etc.

[0104] 2.2 Assemble the ONT sequence and HiFi sequence of the father LCL7 separately.

[0105] 2.21 The HiFi sequence of the father LCL7 was used as the assembly backbone and assembled using the hifiasm software.

[0106] 2.22 The ONT sequence of the father LCL7 was used as the assembly backbone and assembled using Nextdenovo software.

[0107] 2.23 Based on the results of the father LCL7 genome survey in step 2.1, the assembly results of the two lines were de-redundant, and the genome integrity was assessed using BUSCO. The reads were aligned back to remove low-quality contigs, and the human mitochondrial sequences in the NCBI database were aligned to the assembled genome to remove the aligned mitochondrial sequences.

[0108] 2.3 Perform Hi-C mounting on the two assembly versions obtained in step 2.23.

[0109] 2.4 Use the third-generation HiFi sequence to correct errors in the centromere region of the ONT sequence assembly version.

[0110] 2.5 Use the second-generation Illumina sequence to correct the ONT sequence assembly version.

[0111] 2.6 Telomere extension was performed on both assembly versions.

[0112] 2.7 Gap filling: Extract the ONT reads at both ends of the gap that are not aligned to the reference genome or have poor alignment quality (similarity less than 80%, coverage less than 80%), and then use these reads for local iterative assembly to find the best gap filling path to form sequences that overlap with the left and right sides of the gap, and then map them back to the genome containing the gap to replace the corresponding gap region.

[0113] 2.8 Use HiFi sequence to correct the genome after the hole is filled.

[0114] 2.9 Align the assembled version of the father’s LCL7 with T2T-CHM13, adjust the chromosome order, and perform colinearity analysis.

[0115] 2.10 Select the version with the best completeness and accuracy among the two lines as the final T2T genome of father LCL7.

[0116] 3. The second-generation Illumina sequences and third-generation HiFi sequences of the subject LCL5, his father LCL7, and his mother LCL8 were compared with the two haplotype T2T genomes LCL7hap1 and LCL7hap2 assembled by the father LCL7 for mutation detection. For the Illumina sequences, the BWA-MEM software was used for comparison, and then the GATK HaplotypeCaller software was used for SNP and indel detection to obtain the small variants data set (including SNV and indel); for the HiFi sequences, the pbmm2 software was used for comparison, and then the DeepVarient software was used for SNP and indel detection to obtain the smallvariants data set (including SNV and indel), and the sniffles2 software was used for SV detection to obtain the SV data set.

[0117] The number of small variants obtained by comparing the LCL5 Illumina sequence of the subject with different reference genomes was counted. The results are as follows Figure 1 shown. Figure 1 It is the number of small variants obtained by aligning the LCL5 Illumina sequence based on hg19, hg38, T2T-CHM13, and LCL7.

[0118] Figure 1 The results show that compared with the number of small variants obtained based on the traditional reference genomes hg19, hg38, and T2T-CHM13, the number of small variants obtained based on the paternal LCL7 T2T genome alignment is significantly reduced.

[0119] The number of small variants obtained by comparing the LCL5 HiF sequence of the subject with different reference genomes was counted. The results are as follows Figure 2 shown. Figure 2 It is the number of small variants obtained by aligning LCL5 HiFi sequence based on hg19, hg38, T2T-CHM13, and LCL7 respectively.

[0120] Figure 2 The results show that compared with the number of small variants obtained based on the traditional reference genomes hg19, hg38, and T2T-CHM13, the number of small variants obtained based on the paternal LCL7 T2T genome alignment is significantly reduced.

[0121] The number of SVs obtained by comparing the LCL5 HiF sequence of the subject with different reference genomes was counted. The results are as follows Figure 3 shown. Figure 3 is the number of SV variations obtained by aligning the LCL5 HiFi sequence based on hg19, hg38, T2T-CHM13, and LCL7, respectively.

[0122] Figure 3 The results showed that compared with the number of SVs obtained based on the traditional reference genomes hg19, hg38, and T2T-CHM13, the number of SVs obtained based on the paternal LCL7 T2T genome alignment was significantly reduced.

[0123] Experiment 2 assembled the T2T genome of the subject's mother LCL8 as a reference baseline

[0124] 1. Obtain the genome data generated by the publicly available Chinese Pedigree No. 1 standard material. Chinese Pedigree No. 1 is a Quartet pedigree, including parents and a pair of identical twin daughters. In this example, the Illumina sequence, HiFi sequence, ONT sequence, and Hi-C sequence of the twin mother LCL8 are downloaded for the subsequent assembly of the T2T genome of the mother LCL8; the three-generation HiFi sequence of the twin daughter LCL5 and her father LCL7 and mother LCL8 are downloaded for subsequent comparison and variation screening.

[0125] 2. Assemble the T2T genome of mother LCL8. The specific steps include:

[0126] 2.1 The second-generation Illumina sequence of the mother LCL8 was used to conduct a genome survey to estimate the genome size, heterozygosity, repetitive sequence ratio, GC content, etc.

[0127] 2.2 The ONT sequence and HiFi sequence of mother LCL8 were assembled separately.

[0128] 2.21 The HiFi sequence of mother LCL8 was used as the assembly backbone and assembled using the HiFiasm software.

[0129] 2.22 The ONT sequence of mother LCL8 was used as the assembly backbone and assembled using Nextdenovo software.

[0130] 2.23 Based on the results of the mother LCL8 genome survey in step 2.1, the assembly results of the two lines were de-redundant, and the genome integrity was assessed using BUSCO. The reads were aligned back to remove low-quality contigs, and the human mitochondrial sequences in the NCBI database were aligned to the assembled genome to remove the aligned mitochondrial sequences.

[0131] 2.3 Perform Hi-C mounting on the two assembly versions obtained in step 2.23.

[0132] 2.4 Use the third-generation HiFi sequence to correct errors in the centromere region of the ONT sequence assembly version.

[0133] 2.5 Use the second-generation Illumina sequence to correct the ONT sequence assembly version.

[0134] 2.6 Telomere extension was performed on both assembly versions.

[0135] 2.7 Gap filling: Extract the ONT reads at both ends of the gap that are not aligned to the reference genome or have poor alignment quality (similarity less than 80%, coverage less than 80%), and then use these reads for local iterative assembly to find the best gap filling path to form sequences that overlap with the left and right sides of the gap, and then map them back to the genome containing the gap to replace the corresponding gap region.

[0136] 2.8 Use HiFi sequence to correct the genome after the hole is filled.

[0137] 2.9 Align the assembled version of the mother LCL8 with T2T-CHM13, adjust the chromosome order, and perform colinearity analysis.

[0138] 2.10 Select the version with the best completeness and accuracy among the two lines as the final T2T genome of mother LCL8.

[0139] 3. The three-generation HiFi sequences of the subject LCL5 and his father LCL7 and mother LCL8 were compared with the two assembled haplotype T2T genomes of the mother LCL8 for variation detection. The comparison software used was pbmm2, and the variation detection software used was DeepVarient to obtain a small variants data set (including SNVs and indels).

[0140] The number of small variants of LCL5 in the subjects was counted, and the results were as follows Figure 4 shown. Figure 4 It is the number of small variants obtained by aligning LCL5 HiFI sequences based on hg38, T2T-CHM13, and LCL8, respectively.

[0141] Figure 4 The results showed that compared with the number of small variants obtained based on the traditional reference genome hg38 and T2T-CHM13 alignment, the number of small variants obtained based on the mother LCL8 T2T genome alignment was significantly reduced.

[0142] Experiment 3: Assemble the T2T genome of subject LCL5 as a reference baseline

[0143] 1. Obtain the genome data generated by the publicly available Chinese Family No. 1 standard material. Chinese Family No. 1 is a Quartet family, including parents and a pair of identical twin daughters. In this example, the Illumina sequence, HiFi sequence, ONT sequence, and Hi-C sequence of the twin daughter LCL5 are downloaded for the subsequent assembly of the twin daughter LCL5 T2T genome; the three-generation HiFi sequence of the twin daughter LCL5 and its father LCL7 and mother LCL8 are downloaded for subsequent comparison and variation detection.

[0144] 2. Assemble the T2T genome of twin daughter LCL5. The specific steps include:

[0145] 2.1 The second-generation BGI sequence of the twin daughter LCL5 was used to conduct a genome survey to estimate the genome size, heterozygosity, repetitive sequence ratio, GC content, etc.

[0146] 2.2 The ONT sequence and HiFi sequence of the twin daughters LCL5 were assembled separately.

[0147] 2.21 The HiFi sequence of subject LCL5 was used as the assembly backbone and assembled using hifiasm software.

[0148] 2.22 The ONT sequence of the subject LCL5 was used as the assembly backbone and assembled using Nextdenovo software.

[0149] 2.23 Based on the results of the twin daughter LCL5 genome survey in step 2.1, the assembly results of the two lines were de-redundant, and the genome integrity was assessed using BUSCO. The reads were aligned back to remove low-quality contigs, and the human mitochondrial sequences in the NCBI database were aligned to the assembled genome to remove the aligned mitochondrial sequences.

[0150] 2.3 Perform Hi-C mounting on the two assembly versions obtained in step 2.23.

[0151] 2.4 Use the third-generation HiFi sequence to correct errors in the centromere region of the ONT sequence assembly version.

[0152] 2.5 Use the second-generation Illumina sequence to correct the ONT sequence assembly version.

[0153] 2.6 Telomere extension was performed on both assembly versions.

[0154] 2.7 Gap filling: Extract the ONT reads at both ends of the gap that are not aligned to the reference genome or have poor alignment quality (similarity less than 80%, coverage less than 80%), and then use these reads for local iterative assembly to find the best gap filling path to form sequences that overlap with the left and right sides of the gap, and then map them back to the genome containing the gap to replace the corresponding gap region.

[0155] 2.8 Use HiFi sequence to correct the genome after the hole is filled.

[0156] 2.9 Align the assembled version of the twin daughters’ LCL5 with T2T-CHM13, adjust the chromosome order, and perform colinearity analysis.

[0157] 2.10 The version with the best completeness and accuracy in the two lines was selected as the final T2T genome of the twin daughter LCL5.

[0158] 3. The three-generation HiFi sequences of the twin daughter LCL5, her father LCL7, and her mother LCL8 were compared with the assembled T2T genome of the twin daughter LCL5 and the variation detection software was DeepVarient to obtain the small variants data set.

[0159] Count the number of small variants of the mother's LCL8, the results are as follows Figure 5 shown. Figure 5 The number of small variants obtained for LCL8 HiFI sequences based on the alignment of hg38 and LCL5.

[0160] Figure 5 The results show that compared with the number of small variants obtained based on the traditional reference genome hg38 alignment, the number of small variants obtained based on the T2T genome alignment of the twin daughters LCL5 was significantly reduced.

[0161] Furthermore, the variants located in the gap region of the traditional reference genome hg38 can be found in the variant data set obtained in step 3. Here, the small variant obtained by LCL8 HIFI sequence alignment based on LCL5hap1 is taken as an example. The LCL5hap1 genome assembled in step 2 is completely closed on chromosome 6 without gaps. The coordinate interval corresponding to the hg38 gap region in LCL5 hap1 chromosome 6 is obtained through colinearity analysis with hg38. The region of about 58 to 60M in this region is a complex region of the genome. SNPs and indels located in the complex region of the genome are obtained from this interval. Some variants are summarized in Table 1 below.

[0162] Table 1. Some variants located in the complex region of chromosome 6 obtained by alignment of LCL8 HIFI sequence with LCL5hap1

[0163]

[0164]

[0165] Furthermore, the variant dataset obtained in step 3 is annotated and screened to obtain candidate pathogenic variants.

[0166] Furthermore, Mendel's law of inheritance was used to analyze candidate pathogenic variants. Specifically, the variants obtained were processed using DenovoCNN software, and novel variants were obtained after screening and filtering, which can be used to improve the rating of candidate pathogenic variants. The statistical results of novel variants are shown in Table 2.

[0167] Table 2 Some new LCL5 variants obtained after screening and filtering

[0168]

[0169]

[0170]

[0171] Furthermore, for the candidate pathogenic variants obtained, the suspected candidate pathogenic variants can be further confirmed or excluded based on the evidence of family genetic co-segregation. For example, the CSF1R gene is the pathogenic gene of hereditary diffuse leukoencephalopathy with spheroidal body disease, the inheritance pattern is AD, the father has a normal phenotype, and the c.1728G>A variation of the above gene exists in both the father and the daughter, so the pathogenicity of the candidate variation can be preliminarily excluded.

[0172] The above contents are further detailed descriptions of the present application in combination with specific implementation methods, and it cannot be determined that the specific implementation of the present application is limited to these descriptions. For ordinary technicians in the technical field to which the present application belongs, several simple deductions or substitutions can be made without departing from the concept of the present application.

Claims

1. A method for obtaining a genome variation dataset, characterized in that: The following steps are included: The step of obtaining a sequencing sequence includes obtaining the sequencing sequence of the subject to be tested and his / her father and mother; A genome assembly step, comprising assembling a genome of the sequencing sequence of the subject or his / her father or his / her mother, and using the assembled genome as a reference baseline; The step of obtaining a variation data set includes comparing the sequencing sequences of the subject to be tested and its father and mother with the reference baseline respectively and performing variation calling to obtain a variation data set of the subject to be tested.

2. The method according to claim 1, characterized in that The genome assembly is a T2T genome assembly; Preferably, the genome assembly is a haplotype-resolution assembly or a folded-type assembly of a T2T genome assembly; Preferably, the assembled genome satisfies that at least one chromosome is assembled to a telomere-to-telomere gap-free level, and the assembly quality of the entire genome is greater than that of the reference genome GRCh38.

3. A method for detecting genome variation, characterized in that: include 1) Obtaining a genomic variation dataset using the method of claim 1 or 2; 2) annotating the variant dataset; 3) Screening the annotated variant dataset to obtain candidate genomic variants; 4) confirming novel variations among the candidate genomic variations based on Mendel's laws of inheritance; Alternatively, suspected pathogenic variants among the candidate genomic variants are confirmed or excluded based on evidence of co-segregation in the family.

4. A device for obtaining a genome variation data set, characterized in that: The device includes: A sequencing sequence acquisition module is used to obtain the sequencing sequences of the subject to be tested and his or her father and mother; A genome assembly module, used to assemble the genome of the sequencing sequence of the subject to be tested or his father or his mother, and use the assembled genome as a reference baseline; The variant data set acquisition module is used to compare and call variants of the sequencing sequences of the subject to be tested and its father and mother with the reference baseline respectively, so as to obtain the variant data set of the subject to be tested.

5. The device according to claim 4, characterized in that The genome assembly is a T2T genome assembly; Preferably, the genome assembly is a haplotype-resolution assembly or a folded-type assembly of a T2T genome assembly; Preferably, the assembled genome satisfies that at least one chromosome is assembled to a telomere-to-telomere gap-free level, and the assembly quality of the entire genome is greater than that of the reference genome GRCh38.

6. A device for detecting genome variation, characterized in that: The device includes: A sequencing sequence acquisition module is used to obtain the sequencing sequences of the subject to be tested and his or her father and mother; A genome assembly module, used to assemble the genome of the sequencing sequence of the subject to be tested or his father or his mother, and use the assembled genome as a reference baseline; A variant data set acquisition module is used to compare and call variants of the sequencing sequences of the subject to be tested and its father and mother with the reference baseline respectively, to obtain a variant data set of the subject to be tested; An annotation module, used for annotating the variant data set obtained by the variant data set obtaining module; A screening module, used to screen the annotated variant data set to obtain candidate genomic variants; The confirmation module is used to confirm the novel variation among the candidate genomic variation based on Mendel's law of inheritance; or to confirm or exclude the suspected pathogenic variation among the candidate genomic variation based on the evidence of familial genetic co-segregation.

7. A device for obtaining a genome variation data set, characterized in that: The device comprises, Memory, used to store programs; A processor, configured to implement the method for obtaining a genomic variation dataset according to claim 1 or 2 by executing the program stored in the memory.

8. A computer-readable storage medium, characterized in that: The storage medium stores a program, which can be executed by a processor to implement the method for obtaining a genomic variation dataset according to claim 1 or 2.

9. A device for detecting genome variation, characterized in that: The device comprises, Memory, used to store programs; A processor, configured to implement the method for detecting genomic variation according to claim 3 by executing the program stored in the memory.

10. A computer-readable storage medium, characterized in that: The storage medium stores a program, and the program can be executed by a processor to implement the method for genome variation detection according to claim 3.